51985-95-6

Usage

Uses

Used in Pharmaceutical Research and Development:
5-HYDROXY-1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID METHYL ESTER is used as a key intermediate in the synthesis of new drugs for various therapeutic areas. Its unique structure and functional groups allow for the development of innovative pharmaceutical agents with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-HYDROXY-1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID METHYL ESTER is utilized as a building block for the design and synthesis of novel compounds with potential therapeutic properties. Its versatility in chemical reactions enables the creation of diverse drug candidates with tailored pharmacological profiles.
Used in Drug Discovery:
5-HYDROXY-1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID METHYL ESTER is employed in drug discovery processes to identify and optimize lead compounds with promising biological activities. Its presence in compound libraries facilitates high-throughput screening and structure-activity relationship studies, accelerating the discovery of new therapeutic agents.
Used in Chemical Synthesis:
As a methyl ester derivative, 5-HYDROXY-1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID METHYL ESTER is used in various chemical synthesis processes, including the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity and functional groups make it a valuable precursor in the synthesis of a wide range of compounds.
Used in Analytical Chemistry:
5-HYDROXY-1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID METHYL ESTER can be used as a reference compound or a standard in analytical chemistry for the development and validation of analytical methods. Its unique chemical properties and structure make it suitable for use in chromatographic, spectroscopic, and other analytical techniques to ensure accurate and reliable measurements.

InChI:InChI=1/C6H8N2O3/c1-8-5(9)3-4(7-8)6(10)11-2/h3,7H,1-2H3

Upstream product

• 58364-79-7 2-(1-Methylhydrazino)maleinsaeure-dimethylester 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 60-34-4 methylhydrazine 
• 246539-64-0 ethyl methoxalylacetate 
• 70609-03-9 2-(1-Methylhydrazino)maleinsaeure-6>dimethylester 

Downstream Products

• 1222174-92-6 5-bromo-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 1617523-10-0 5-bromo-N-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide 
• 1349698-77-6 4-[({5-[2-ethoxymethyl-1-(2-(trimethylsilanyl)ethoxymethyl)-1H-indol-5-yl]-1-methyl-1H-pyrazole-3-carbonyl}amino)methyl]benzoic acid 
• 1349698-71-0 C₁₄H₁₄BrN₃O₃ 
• 1349698-70-9 (4-{[(5-bromo-1-methyl-1H-pyrazole-3-carbonyl)amino]methyl}phenyl)acetic acid methyl ester 
• 1222174-97-1 4-{[(5-bromo-1-methyl-1H-pyrazole-3-carbonyl)amino]methyl}benzoic acid 
• 1222174-94-8 4-{[(5-bromo-1-methyl-1H-pyrazole-3-carbonyl)amino]methyl}benzoic acid methyl ester 
• 1222174-93-7 5-bromo-1-methyl-1H-pyrazole-3-carboxylic acid 
• 1222174-95-9 4-({[5-(2-ethoxymethyl-1H-indol-5-yl)-1-methyl-1H-pyrazole-3-carbonyl]amino}methyl)bezoic acid 
• 1222173-84-3 4-({[5-(1H-indol-5-yl)-1-methyl-1H-pyrazole-3-carbonyl]-amino}-methyl)bezoic acid 
• 1222173-70-7 5-[5-(4-carboxy-benzylcarbamoyl)-2-methyl-2H-pyrazol-3-yl]-1H-indole-2-carboxylic acid 
• 1222173-43-4 5-[5-(4-carboxymethyl-benzylcarbamoyl)-2-methyl-2H-pyrazol-3-yl]-1H-indole-2-carboxylic acid ethyl ester 
• 1222173-37-6 5-[5-(4-carboxybenzylcarbamoyl)-2-methyl-2H-pyrazol-3-yl]-1H-indole-2-carboxylic acid ethyl ester 
• 58364-91-3 5-methoxy-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, A and B are as defined herein. The invention also r

Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13

Matrix metalloproteases (MMPs) play an important role in cartilage homeostasis under both normal and inflamed disease states and, thus, have become attractive targets for the treatment of arthritic diseases. Herein, we describe the identification of a pot

ISOXAZOLE-PYRAZOLE DERIVATIVES

The present invention is concerned with isoxazole-pyrazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors

A novel class of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as c-Jun-N-terminal kinase (JNK) inhibitors is described. These compounds were synthesized via the condensation of 2-nitrobenzaldehydes and hydroxypyrazoles. The structure-activity relationships (SAR) and kinase selectivity profile of the inhibitors are also discussed. Compound 16 was identified as a potent JNK inhibitor with good cellular potency.

Substituted pyrazole derivatives

New substituted pyrazole derivatives of general formula I are described STR1 in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description, processes for their preparation, as well as intermediates, and their use as herbicides.

Substituted pyrazolypyrazoles and their use as herbicides

STR1 The invention relates to new pyrazolylpyrazoles of general formula (I) in which R1, R2, R3, R4 and R5 have the meanings given in the description, processes for their preparation as well as intermediates, and their use as herbicides.

Enehydrazines, 34. The Addition of Methylhydrazine to Dimethyl Acetylenedicarboxylate is Reversible

The cyclisation of the enehydrazine 1 to the pyrazolone 5 proceeds by cleavage of 1 to its educts 2 and 3 followed by their recombination to 4.Addition of 2 or 3 supresses the dissociation of 1, furthermore 2 and 3 could be separately captured from 1.

Enehydrazines, 35. Dimethyl-2-fumarate

Reaction of the pyrazolone 4 with dimethyl acetylenedicarboxylate gives the title compound 1, the crystal structure analysis of which is presented.Heating of 1 leads to the lactone 2, which was synthesized through an independent route.